Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Progenics Pharmaceuticals (NASDAQ:PGNX) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Progenics and see what CAPS investors are saying about the stock right now.

Progenics facts

Headquarters (founded)

Tarrytown, N.Y. (1986)

Market Cap

$245.9 million

Industry

Biotechnology

Trailing-12-Month Revenue

$14.1 million

Management

CEO Mark Baker (since 2011)
CFO Angelo Lovallo Jr. (since 2011)

Trailing-12-Month Return on Equity

(42.7%)

Cash/Debt

$55.3 million / $0

Competitors

Dendreon
Nektar Therapeutics

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 10% of the 187 members who have rated Progenics believe the stock will underperform the S&P 500 going forward.

One of those Fools, All-Star zzlangerhans, tapped yesterday's huge surge as particularly unsustainable:

Progenics is a highly volatile stock at the moment, which makes it a great stock for skilled swing traders and a terrible stock for the unskilled ones. [T]he stock is up ... with no specific catalyst other than [Monday's] ho-hum press release regarding prostate cancer imaging agents acquired from failed biopharma outfit Molecular Insight. There's no good reason for the price spike to have occurred, let alone be sustained, which means it probably will be. Meanwhile, as I've stated many times previously, the long-term prospects of the company are bad as Relistor is a dead end and PSMA has been the light at the end of the tunnel for six years and counting.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.